- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
- Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
- Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
More ▼
Key statistics
As of last trade, Terns Pharmaceuticals Inc (TERN:NSQ) traded at 5.82, 78.53% above the 52 week low of 3.26 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.83 |
---|---|
High | 5.95 |
Low | 5.77 |
Bid | 5.81 |
Offer | 5.83 |
Previous close | 5.79 |
Average volume | 655.44k |
---|---|
Shares outstanding | 64.67m |
Free float | 62.40m |
P/E (TTM) | -- |
Market cap | 374.47m USD |
EPS (TTM) | -1.27 USD |
Data delayed at least 15 minutes, as of May 07 2024 16:31 BST.
More ▼